第五要素:血管功能障碍是痛风的固有特征吗
痛风除无症状高尿酸血症、急性发作、发作间期和痛风石四种表型状态外,还存在血管受累这一第五种状态;可溶性尿酸盐在体外和动物模型中损害血管内皮和平滑肌,并可经细胞内转运改变细胞代谢和表观遗传;痛风患者内皮功能减退,遵循ACR痛风指南的治疗可改善内皮功能,但在合并心血管代谢共病者中效果较差。
要点
- 痛风除四种经典表型状态外,还存在血管受累这一第五种状态。
- 可溶性尿酸盐在体外和动物模型中损害血管内皮和平滑肌。
- 痛风患者肱动脉血流介导的舒张功能测定的内皮功能减退。
核心结论
- 作者提出血管受累是痛风的第五种状态,其机制和后果尚未完全阐明。
研究设计与样本
- 本文为综述,围绕体外与动物模型证据、可溶性尿酸盐的细胞内转运及临床内皮功能研究汇总痛风的血管受累。
主要发现
- 体外和动物模型显示可溶性尿酸盐对血管内皮和平滑肌有不良影响。
- 可溶性尿酸盐可被转运至细胞内改变细胞代谢和表观遗传(训练天然免疫)。
- 痛风进展至发作后,血管在发作期及发作间期持续但程度较轻地暴露于炎症介质。
- 痛风患者经肱动脉血流介导的舒张功能测定的内皮功能减退。
- 遵循ACR痛风指南的治疗可改善内皮功能,但在合并心血管代谢共病的患者中效果较差。
关键数值与推荐
- 痛风影响多达5.1%的成年人群。
- 秋水仙碱联合降尿酸治疗可改善痛风患者的内皮功能,并降低新发冠状动脉疾病(CAD)和已确诊CAD患者主要不良心血管事件(MACE)的风险。
临床怎么用
- 遵循ACR痛风指南的治疗可改善内皮功能,但在合并心血管代谢共病的患者中效果较差。
- 抗炎药秋水仙碱联合降尿酸治疗可改善痛风患者内皮功能,并降低新发CAD及已确诊CAD患者MACE风险。
局限性
- 血管性痛风的机制和后果尚未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gout, the most common inflammatory arthritis, affects as many as 5.1% of the adult population. Classically, gout is conceived as four sequential phenotypic states: 1) asymptomatic hyperuricemia 2) acute gout flare 3) inter-critical gout (gout between flares); and 4) tophaceous gout. However, these four states are paralleled by a fifth state, consisting of vascular involvement. The mechanisms and consequences of vascular gout are incompletely elucidated. In vitro and animal models indicate that soluble urate adversely affects vascular endothelium and smooth muscle. The recent discovery that soluble urate can be transported intracellularly to alter cell metabolism and epigenetics (trained innate immunity) suggests additional impacts of urate on leukocytes and endothelium. Once gout has progressed to flares, the vasculature is exposed to inflammatory mediators, both during flares and to a lesser but persistent extent inter-critically, suggesting additional mechanisms of gout's effect. We have reported that patients with gout have diminished endothelial function measured by brachial artery flow-mediated dilation. ACR gout guideline-concordant treatment improves endothelial function but is less effective in patients with cardiometabolic comorbidities. Moreover, treatment of gout patients with the anti-inflammatory colchicine and urate lowering therapy improves endothelial function and reduces the risk of both incident coronary artery disease (CAD), and MACE in patients with established CAD.
引用
- Pillinger MH, Toprover M. The Fifth Element: Is Vascular Dysfunction an Intrinsic Feature of Gout? Semin Arthritis Rheum. 2025. PMID: 40021439. doi:10.1016/j.semarthrit.2025.152679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。